





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/510,923

Confirmation No.: 4889

Applicant

Yoon et al.

Filed

October 8, 2004

Int. App. No. Int. Filing Date PCT/KR02/00627

Art Unit

April 9, 2002

Examiner

1614

Not yet assigned

For

PYRANOCOUMARIN DERIVATIVES

Docket No.

88-04

Customer No. :

23713

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant received a Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed April 21, 2005, (copy attached). However, this application does not contain nucleotide or amino acid sequences. Therefore there is no basis for filing a sequence listing.

Please issue a Filing Receipt for this application.

Respectfully submitted,

Heeia Yoo-Warren Reg. No. 45,495

GREENLEE, WINNER AND SULLIVAN, P.C. 4875 Pearl East Circle, Suite 200

Boulder, CO 80301

Telephone (303) 499-8080 Facsimile: (303) 499-8089 Email: winner@greenwin.com

Attorney Docket No.: 88-04

bmk: April 29, 2005

CERTIFICATE OF TRANSMISSION

hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office at 703-746-6705.

Page 1 of 2



INITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Putent and Trademark Office Address COMMISSIONER FOR PATENTS FO. DO: 1450 Alexandra, Viginta 22313-1410 www.usplo.gov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 88-04 Jeong-Seon Yoon 10/510,923 INTERNATIONAL APPLICATION NO.

PCT/KR02/00627 PRIORITY DATE

LA. FILING DATE

04/09/2002

GREENLEE WINNER AND SULLIVAN 4875 PEARL EAST CIRCLE SUITE 200 BOULDER, CO 80301

CONFIRMATION NO. 4889 371 FORMALITIES LETTER HATER VICENCIA CON CONTRA POR CONTRA CON OC000000015760062

Date Mailed: 04/21/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DOCKETED APR **2 7** 2005

ENTO APR 2 5 2005

04/29/2005 14:44 FAX 303499

Rec'd PCT/PTO

29 APR 2003

421004

Page 2 of 2

GREENLEE WINNER SULLIVA

.. -- ;


BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/510.923	PCT/KR02/00627	88-04

FORM PCT/DO/EO/922 (371 Formalities Notice)



Telephone (303) 499-8080 Fax (303) 499-8089

FACSIMILE COVER SHEET

DATE:

April 29, 2005

TOTAL NO. PAGES:

4 (including cover page)

TO:

Barbara A. Campbell

FIRM NAME:

USPTO

FACSIMILE NUMBER:

703-746-6705

FROM:

Heeja Yoo-Warren

RE:

USSN 10/510,923

Our docket no. 88-04

MESSAGE:

Transmitted herewith:

Response to Notification to Comply

Notification to Comply ... Sequence Disclosures

If transmission is unclear, please telephone (303) 499-8080 immediately and ask for Brenda.

CONFIDENTIALITY NOTICE

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosing, copying, distributing or the taking of any action in reliance on the contents of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone (call collect) and return the original to us at the above address via the postal service. Thank you.